Qiagen N.V. (Qiagen), a provider of sample and assay technologies, has awarded a contract to Plexus Corp (Plexus) to create an automated screening tool for preprocessing DNA specimens of the human papillomavirus (HPV) DNA samples. This product provides an automated solution to a current manual process, through sophisticated robotic motions. The contract builds on the existing collaboration between the two firms that created the initial prototypes.
We are thrilled about our partnership with QIAGEN, as it pairs two companies to create an industry leading product, stated Steve Frisch, senior vice president, global engineering services. Plexus sees this relationship as an indication of how we can utilize our full suite of engineering capabilities, coupled with our complete Product Realization Services, to provide mechatronic solutions for our customers developing complex medical equipment.
Plexus’ proven track record of assisting customers in bringing complex medical devices to market, coupled with its ability to quickly staff this program from its five Global Design Centers, made them an ideal partner, commented Dr. Jim Godsey, senior vice president, North America Research & Development at QIAGEN. Thanks to this partnership we will be able offer a unique frontend solution for our next generation high through-put screening platform, which will help Qiagen further maintain its market in the Life Sciences and diagnostics markets.